In-depth coverage of ART management, disease staging, opportunistic infection protocols, special populations, and the unique legal and epidemiological context of HIV care in the Gulf.
ⓘ
HIV is a retrovirus that attacks CD4+ T-lymphocytes. Without treatment, progressive immunodeficiency leads to AIDS-defining illnesses. Understanding staging guides treatment initiation and OI prophylaxis decisions.
WHO Clinical Staging
Stage I — Asymptomatic
Asymptomatic HIV infection. Persistent generalised lymphadenopathy (PGL). Normal activity. CD4 typically >500 cells/mm³.
Stage II — Mild Symptoms
Minor mucocutaneous manifestations: seborrhoeic dermatitis, prurigo, fungal nail infections, recurrent oral ulcerations, angular cheilitis. Herpes zoster within past 5 years. Recurrent upper respiratory tract infections. Weight loss <10% body weight.
Stage III — Advanced Symptoms
Unexplained weight loss >10% body weight. Chronic unexplained diarrhoea >1 month. Prolonged unexplained fever >1 month. Oral candidiasis (thrush) or oral hairy leukoplakia. Pulmonary tuberculosis (current). Severe bacterial infections (pneumonia, meningitis, septicaemia). Acute necrotising stomatitis/gingivitis. Unexplained anaemia (<8 g/dL), neutropaenia, or thrombocytopaenia.
Stage IV — AIDS-Defining Illnesses
PCP: Pneumocystis jirovecii pneumonia. CMV: Cytomegalovirus retinitis or other organ involvement. Toxoplasmosis: Cerebral toxoplasmosis. MAC: Disseminated Mycobacterium avium complex. Cryptococcosis: Cryptococcal meningitis or disseminated infection. Kaposi's Sarcoma: Any site. Wasting syndrome: >10% weight loss + chronic diarrhoea or unexplained fever. HIV-related encephalopathy, CNS lymphoma, disseminated endemic mycoses, recurrent Salmonella bacteraemia.
CD4 Count Interpretation
500–1500
Normal CD4 range (cells/mm³)
<350
ART initiation threshold — all patients
<200
AIDS definition + high OI risk
<50
Severe AIDS — MAC/CMV risk
CD4 Count
Clinical Implication
Action
>500
Normal immune function — WHO Stage I/II
Monitor 6-monthly; initiate ART per WHO 2021
350–499
Declining immunity — increased OI susceptibility
ART initiation; 3–6 monthly monitoring
200–349
Significant immunosuppression — AIDS threshold
ART; cotrimoxazole prophylaxis; 3-monthly CD4
<200
AIDS — high PCP/Toxo risk
Urgent ART; cotrimoxazole prophylaxis essential
<50
Severe AIDS — MAC/CMV/Crypto risk
MAC prophylaxis; ophthalmology; hospitalise if unwell
U=U (Undetectable = Untransmittable): Patients with sustained undetectable VL cannot sexually transmit HIV. This message reduces stigma and improves treatment motivation. Nurses have a key role in communicating this.
📋
Monitoring Schedule
Baseline VL at diagnosis
Repeat VL at ART initiation
VL at 3 months after ART start
VL at 6 months after ART start
6-monthly VL once suppressed
CD4 at baseline; repeat if VL unsuppressed or clinical concern
Resistance testing before regimen change
Primary HIV Infection — Acute Retroviral Syndrome
⚠
Acute Retroviral Syndrome (ARS)
Occurs 2–4 weeks post-exposure in 50–90% of individuals. High VL, rapid CD4 decline, and high transmissibility during this window period.
COMMON SYMPTOMS
Fever (96%)
Lymphadenopathy (74%)
Pharyngitis (70%)
Erythematous maculopapular rash (70%)
Myalgia/arthralgia (54%)
Oral ulcers/thrush (32%)
Night sweats, headache, diarrhoea
DIAGNOSTIC NOTE
⚠
HIV antibody tests may be negative during ARS (window period). Order HIV RNA/PCR or 4th-generation Ag/Ab combination test. Diagnose early — immediate ART reduces transmission and reservoir size.
📊 CD4 / Viral Load Monitoring Tracker
Enter the patient's current values to receive a treatment response assessment, OI risk level, and prophylaxis checklist.
●
WHO 2021 recommends ART for ALL people living with HIV, regardless of CD4 count. Early initiation reduces transmission, AIDS complications, and non-AIDS morbidity. Same-day or rapid ART start is preferred when clinically safe.
BACKBONE of all regimens (2 NRTIs + 1 third agent)
Drug
Key Points
TDF Tenofovir DF
Preferred backbone; active against HBV co-infection; monitor renal function/phosphate
FTC Emtricitabine
Paired with TDF (Truvada/Descovy); active against HBV
3TC Lamivudine
Alternative to FTC; also HBV-active; well tolerated
ABC Abacavir
HLA-B*5701 testing BEFORE starting — hypersensitivity reaction risk (potentially fatal)
⚠
HBV Co-infection: NEVER stop TDF/FTC or 3TC in HBV+HIV co-infected patients without an alternative HBV-active agent — risk of HBV flare and hepatic decompensation.
CNS side effects (vivid dreams, dizziness, depression) — take at bedtime. AVOID in 1st trimester pregnancy — neural tube defect risk (neuroteratogenic)
RPV Rilpivirine
Must take with a full meal (≥390 kcal); avoid with PPIs; active against EFV-resistant strains
DOR Doravirine
Newer NNRTI; fewer CNS effects; can be taken without food
💊
PIs — Protease Inhibitors
Require pharmacokinetic boosting with ritonavir (RTV) or cobicistat (COBI)
Drug
Key Points
DRV/r Darunavir/ritonavir
Preferred PI; high genetic barrier to resistance; GI side effects
LPV/r Lopinavir/ritonavir
Used in resource-limited settings; significant GI side effects; lipodystrophy
⚠
PI Class Effects: Dyslipidaemia, lipodystrophy (fat redistribution — buffalo hump, lipoatrophy), GI intolerance, hepatotoxicity. Monitor lipids, LFTs, glucose. Significant drug-drug interactions (CYP3A4).
💊
INSTIs — Integrase Strand Transfer Inhibitors
Gold standard first-line agents — high potency, high barrier to resistance
Drug
Key Points
DTG Dolutegravir
WHO-preferred first-line. Pregnancy safe (preferred). High barrier. Insomnia/weight gain reported. Avoid with antacids/cations ±2h.
BIC Bictegravir
In Biktarvy (BIC/FTC/TAF); once daily; no food requirement; high barrier
RAL Raltegravir
Twice daily; lower barrier than DTG; well tolerated; safe in pregnancy
CAB Cabotegravir LA
Long-acting injectable (with rilpivirine); monthly or every-2-month dosing
Preferred First-Line Regimens
WHO 2021 PREFERRED ORAL REGIMEN
●
TDF + FTC (or 3TC) + DTG
Once daily. High potency. High barrier to resistance. Pregnancy safe. TDFFTC/3TCDTG
Alternative oral: TDF + FTC + EFV400 (not 1st trimester pregnancy) or ABC + 3TC + DTG (after HLA-B*5701 testing).
LONG-ACTING INJECTABLE (2-DRUG REGIMEN)
💉
Cabotegravir + Rilpivirine LA
Monthly or every-2-month IM injections. For virologically suppressed patients. Eliminates daily pill burden. Must take with meal. Not if CD4<200 or VL>50. CAB LARPV LA
ART in Pregnancy
♥
Pregnancy-Specific ART Considerations
DTG is the preferred INSTI in pregnancy (all trimesters, including 1st trimester per WHO 2021 updated guidance — neural tube defect risk very low)
EFV avoid in 1st trimester — historical neuroteratogenicity concern
Continue TDF + FTC/3TC backbone (renal function monitoring)
ART reduces vertical transmission to <1% if VL undetectable
C-section if VL >1,000 copies/mL near delivery
Infant ARV prophylaxis: Nevirapine (NVP) syrup × 6 weeks
Early infant diagnosis: PCR at 4–6 weeks of age
In GCC: formula feeding generally safe (safe water access); breastfeeding decisions require individualised counselling
Monitor mother: LFTs, renal function, FBC throughout
Maternal VL at delivery: target undetectable
⚠
Opportunistic infections (OIs) are the leading cause of morbidity and mortality in people with HIV. Primary prophylaxis prevents first OI episodes; secondary prophylaxis prevents recurrence. All indications are CD4-threshold driven.
OI Prophylaxis & Treatment Summary
OI
Prophylaxis Indication
Prophylaxis Agent
Treatment
Stop Prophylaxis When
PCP
CD4 <200 cells/mm³
Co-trimoxazole 480mg OD
Co-trimoxazole 960mg TDS × 21 days + steroids if severe (PaO₂ <70 mmHg)
IRIS occurs when ART restores immunity and causes a paradoxical inflammatory response to existing or subclinical infections.
Paradoxical IRIS: Worsening of known OI after ART initiation
Unmasking IRIS: New OI presentation after ART initiation
Risk: Low CD4 at ART start, early ART initiation in OI setting
Common triggers: TB, CMV, Cryptococcus, MAC
Management: Continue ART (usually); NSAIDs/steroids for moderate-severe; treat underlying OI
Cryptococcal IRIS: High mortality — delay ART 4–6 weeks post-fluconazole
Cryptococcal Meningitis — Nursing Management
💭
Raised Intracranial Pressure (ICP) Management
ICP elevation is the major cause of early mortality in cryptococcal meningitis. Therapeutic LPs are essential.
Measure opening pressure on ALL LPs in cryptococcal meningitis
Remove CSF to normalise pressure if opening pressure >25 cmH₂O
Daily therapeutic LPs until pressure normalised
Do NOT use acetazolamide or steroids for ICP in Crypto
Monitor for herniation signs: drowsiness, cranial nerve palsies, papilloedema
NURSING OBSERVATIONS
GCS and focal neurological signs hourly initially
Strict headache score monitoring
Vision changes — urgent ophthalmology
Post-LP monitoring: BP, HR, positioning
Fluconazole blood levels if poor response
HIV in Pregnancy
♥
Prevention of Vertical Transmission (PMTCT)
ⓘ
Vertical transmission risk: 15–45% without intervention → <1% with optimal ART + obstetric management. Four key components: ART, mode of delivery, feeding choice, infant prophylaxis.
Initiate ART immediately regardless of CD4 or gestation
Target: undetectable VL by delivery
C-section if VL >1,000 copies/mL at 38 weeks
In GCC: formula feeding recommended where safe water accessible (reduces transmission to near zero)
Infant NVP prophylaxis × 6 weeks
HIV PCR at 4–6 weeks of age (antibody testing not valid until 18 months)
⚠
GCC Immigration Note: HIV-positive pregnant women (especially expatriates) may face deportation. This creates barriers to antenatal disclosure and treatment. Nurses must maintain strict confidentiality and provide non-judgemental care regardless of immigration status.
HIV in Women
♡
Sex-Specific Considerations
Biologically more susceptible to HIV than men (mucosal surface area, microtrauma)
Cervical cancer screening: 6-monthly Pap smear if CD4 <200
HPV vaccination recommended (up to age 45 in HIV+)
Menstrual irregularities common — monitor for amenorrhoea (OI, weight loss, ART effects)
Osteoporosis risk — TDF + low oestrogen combined
Contraception counselling (interactions with ART and hormonal methods)
EFV reduces ethinyl oestradiol levels by 37% — non-hormonal or alternative contraception
Rilpivirine increases ethinyl oestradiol — minor interaction, monitorable
DTG: no significant contraceptive interactions
STI screening 3-monthly (chlamydia, gonorrhoea, syphilis)
DEXA scan baseline if on TDF or corticosteroids
HIV in Older Adults
💰
Ageing with HIV — Accelerated Ageing Syndrome
People living with HIV on ART live into older age but experience age-related comorbidities 10–15 years earlier than HIV-negative peers due to chronic immune activation and ART toxicity.
ACCELERATED AGE-RELATED CONDITIONS
Cardiovascular disease (early atherosclerosis — HIV inflammation + PI dyslipidaemia)
Bone density loss and fractures (TDF, chronic inflammation, low vitamin D)
Report ALL occupational exposures immediately to Occupational Health
Post-exposure prophylaxis (PEP): start within 1–2 hours; up to 72 hours maximum
PEP regimen: TDF + FTC + DTG × 28 days
Baseline and 6-week/3-month HIV serology
⚠
GCC Context: Healthcare workers living with HIV have faced job loss and deportation in GCC countries. Disclosure obligations vary by country. Nurses must be aware that HIV-positive HCWs face significant professional and legal vulnerability. Advocacy and confidentiality are essential.
⚠
Critical threshold: >95% adherence is required for consistent viral suppression. Missing just 5% of doses can lead to detectable viraemia and, over time, drug resistance. Resistance accumulates silently — by the time it is detected, multiple mutations may have developed.
Adherence Barriers & Strategies
❌
Common Adherence Barriers
Pill burden: Multiple tablets, complex schedules
Side effects: Nausea, diarrhoea, fatigue, CNS effects (EFV)
Stigma: Fear of discovery by family/employer
Depression & mental health: Depression reduces adherence by 3-fold
Smoking cessation; antihypertensives; statins; switch PI → INSTI
HAND (Neurocognitive)
EFV-associated CNS effects; HIV itself
Annual cognitive screen (MoCA); neuropsychology
Optimise ART CNS penetration; switch EFV if contributing; treat depression
Treatment as Prevention (TasP)
🌐
U=U — Undetectable = Untransmittable
The PARTNER, HPTN 052, and Opposites Attract studies collectively demonstrated ZERO onward HIV transmissions from partners with undetectable viral load (<200 copies/mL) during condomless sex. This is the most powerful treatment adherence message available.
NURSE'S ROLE IN U=U
Communicate U=U clearly at every relevant consultation
Document viral load achievement and use it as positive reinforcement
Address misconceptions — many patients (and nurses) are unaware of U=U
Reduce stigma in practice — U=U challenges the "danger" narrative
In GCC context: U=U may be culturally sensitive but remains medically valid
●
PrEP (Pre-Exposure Prophylaxis): TDF/FTC daily for HIV-negative high-risk individuals. Highly effective (>99% adherent use). Limited availability in GCC but available in Dubai (DHA) and some Saudi hospitals. Nurses can provide PrEP education and counselling.
📋 ART Adherence Risk Screener
A 5-question clinical screening tool. Answers generate an adherence risk level with targeted nursing support strategies.
1. How often do you forget to take your HIV medications?
2. Are you currently experiencing significant side effects from your ART?
3. Are you worried that someone will discover your HIV status if they see you taking medication?
4. Do you currently have depression, anxiety, or use alcohol/substances that affect your daily routine?
5. How confident are you that you can take your HIV medication every day for the long term?
⚠
Critical GCC Context: HIV care in Gulf countries is profoundly shaped by legal criminalisation, deportation policies, and deep cultural stigma. Nurses must understand this context to provide safe, non-judgemental, confidential care. Failing to protect confidentiality may directly harm patients.
GCC HIV Epidemiology
<0.1%
HIV prevalence in GCC general population (UNAIDS)
Rising
Trend in cases among key populations in some GCC states
Deported
Outcome for most HIV+ expatriates on mandatory screening
🌏
Epidemic Profile
KEY POPULATIONS
Sex workers (both male and female)
Men who have sex with men (MSM)
People who inject drugs (PWID)
Migrant workers (from high-prevalence countries)
Prisoners (limited data)
STRUCTURAL FACTORS
Mandatory HIV testing on employment/visa entry for most expatriates
Positive result → deportation without treatment initiation in most GCC states
Religious and social norms: homosexuality and sex work are criminalised
No harm reduction programmes (needle exchange, opioid substitution) in most GCC states
GCC HIV Legislation
Country
HIV Testing Policy
HIV+ Expatriate
Anonymous Testing
Free ART for Nationals
UAE (Dubai)
Mandatory on work visa; antenatal
Deportation
DHA anonymous testing available
Yes (MOHAP)
Saudi Arabia
Mandatory work/residency/Hajj
Deportation
Very limited
Yes (MOH)
Qatar
Mandatory work/residency
Deportation
Limited availability
Yes
Kuwait
Mandatory work/residency
Deportation
Not widely available
Yes
Bahrain
Work/residency testing
Deportation
Limited
Yes
Oman
Mandatory work/residency
Deportation
Limited
Yes
Nursing Ethical Practice in GCC HIV Care
🔒
Confidentiality — Non-Negotiable
HIV status is strictly protected health information under all GCC health regulations
Do NOT disclose HIV status to employers, immigration authorities, or family without explicit informed consent
Document HIV status only in clinical records with restricted access
Informed consent for HIV testing — voluntary (except mandatory employment screening)
Provide pre- and post-test counselling for all diagnostic tests
Be aware: inadvertent disclosure (leaving results visible, discussing in ward) has led to patient deportation and job loss
♥
Non-Judgmental Approach to Key Populations
Nurses may care for patients whose behaviours are illegal in the GCC (MSM, sex workers, PWID). The nurse's role is healthcare provision, not moral judgement or legal enforcement.
Provide identical quality of care regardless of mode of HIV acquisition
Do not ask about sexual orientation unless clinically indicated
Harm reduction counselling remains appropriate even where programmes are illegal
Recognise patient fear of disclosure — acknowledge it, address it, protect against it
Refer to mental health services — high rates of depression/suicidality in HIV+ patients in stigmatising environments
Treatment Interruption Risk — Expatriates
⚠
Interrupted ART — Clinical Consequences
Expatriates in GCC may be deported mid-treatment, or may lose employment and healthcare access. Treatment interruption leads to rapid VL rebound (within 1–2 weeks), CD4 decline, and resistance risk if restarted after subtherapeutic levels.
⚠
Nursing Action: When an HIV+ expatriate patient is at risk of deportation or loss of healthcare access, work with social work and infectious disease teams to ensure: (1) medication supply to cover transition; (2) onward referral letter for receiving country; (3) documentation of current regimen and resistance history; (4) contact details for local HIV services in home country.
ⓘ
10 clinical MCQs covering HIV disease progression, ART management, opportunistic infections, and GCC-specific nursing considerations. Select an answer to receive instant feedback.
0 / 10
Questions answered correctly
1. A patient with HIV has a CD4 count of 160 cells/mm³. Which opportunistic infection prophylaxis is MOST urgently indicated?
A Azithromycin 1200mg weekly
B Co-trimoxazole 480mg once daily
C Fluconazole 200mg once daily
D Isoniazid 300mg once daily
Co-trimoxazole prophylaxis is indicated when CD4 <200 cells/mm³ to prevent PCP (and Toxoplasma). Azithromycin is for MAC prophylaxis (CD4 <50). Fluconazole is for cryptococcal disease. Isoniazid is for latent TB prevention.
2. A pregnant woman with HIV is 8 weeks gestation. Which antiretroviral regimen is currently WHO-preferred?
A TDF + FTC + Efavirenz 600mg
B AZT + 3TC + Lopinavir/ritonavir
C TDF + FTC + Dolutegravir
D ABC + 3TC + Raltegravir
WHO 2021 recommends TDF + FTC + DTG as the preferred regimen in pregnancy including the first trimester. Efavirenz was historically avoided in early pregnancy due to neural tube defect concerns, though updated evidence has significantly revised this risk. Dolutegravir is now considered safe and preferred.
3. A patient with cryptococcal meningitis and HIV has an opening CSF pressure of 32 cmH₂O. What is the PRIORITY nursing/clinical action?
A Administer IV dexamethasone immediately
B Start acetazolamide to reduce ICP
C Perform therapeutic lumbar puncture to normalise pressure
D Initiate ART immediately to restore immunity
Therapeutic LP is the cornerstone of raised ICP management in cryptococcal meningitis. Remove CSF to normalise pressure (<20 cmH₂O). Steroids and acetazolamide are NOT recommended in crypto ICP and may be harmful. ART should be delayed 4–6 weeks to avoid IRIS.
4. A patient is started on rifampicin for TB while taking dolutegravir. What is the correct ART adjustment?
A Stop dolutegravir and start lopinavir/ritonavir
B Increase dolutegravir to 50mg twice daily
C Keep dolutegravir at 50mg once daily — no change needed
D Switch to tenofovir alafenamide monotherapy
Rifampicin induces CYP3A4 and reduces dolutegravir levels by ~57%. The correct adjustment is to increase DTG to 50mg BD (twice daily). PIs must NOT be used with rifampicin due to critically reduced PI levels. Rifabutin is an alternative TB drug that has fewer interactions if PI is essential.
5. What does U=U mean in clinical HIV management?
A Undisclosed = Untreatable
B Undertreated = Unsafe
C Undetectable = Untransmittable
D Undetectable = Uncurable
U=U stands for Undetectable = Untransmittable. Evidence from PARTNER (2019), HPTN 052, and Opposites Attract studies shows zero sexual transmissions from partners with sustained undetectable viral load (<200 copies/mL). This message is a key adherence motivator and stigma-reduction tool.
6. A patient on tenofovir disoproxil fumarate (TDF)-based ART develops a gradual rise in serum creatinine and hypophosphataemia. What is the most likely diagnosis and correct action?
A HIV nephropathy — no ART change needed
B Contrast nephropathy — hydrate patient
C TDF-induced proximal tubular toxicity (Fanconi syndrome) — switch to TAF
D Cotrimoxazole nephrotoxicity — stop prophylaxis
TDF can cause proximal renal tubular toxicity presenting with raised creatinine, hypophosphataemia, glycosuria, and proteinuria (Fanconi-like syndrome). The appropriate action is to switch from TDF to TAF (tenofovir alafenamide), which has a much lower renal and bone toxicity profile.
7. A patient presents with fever, rash, pharyngitis, and lymphadenopathy 3 weeks after a potential HIV exposure. The HIV antibody test returns negative. What is the CORRECT interpretation?
A HIV infection is definitively excluded
B Patient has a viral URI — no further action needed
C Possible acute retroviral syndrome — order HIV RNA/PCR or 4th-generation Ag/Ab test
D Patient requires repeat antibody test in 2 years
This is a classic presentation of Acute Retroviral Syndrome (ARS). The HIV antibody test may be negative during the window period (2–4 weeks). A 4th-generation combination Ag/Ab test or HIV RNA PCR must be ordered to detect acute infection. Early diagnosis allows immediate ART initiation and prevents transmission.
8. Before prescribing abacavir (ABC), what is the mandatory screening test?
A G6PD deficiency screening
B CYP2D6 genotyping
C HLA-B*5701 genotyping
D Cryptococcal antigen test
HLA-B*5701 testing is mandatory before starting abacavir. Carriers of HLA-B*5701 have up to 55–60% risk of severe, potentially fatal hypersensitivity reaction (ABC HSR) characterised by fever, rash, and multi-organ involvement. If positive, ABC must NEVER be prescribed. If negative, ABC can be used safely.
9. An HIV-positive expatriate nurse in a GCC country discloses their status to you privately. What is your PRIMARY obligation?
A Report to the nursing manager for infection control purposes
B Notify the hospital occupational health department immediately
C Maintain strict confidentiality and provide support, referring to HIV care services
D Inform immigration authorities as required by law
Confidentiality is the primary obligation. HIV status is protected health information. Unauthorised disclosure could result in the nurse's deportation, job loss, and psychological harm. There is no automatic requirement to report to managers, immigration, or occupational health without consent. Provide compassionate support and referral to HIV services. Legal obligations vary by jurisdiction — seek guidance from ethics/legal teams if genuinely uncertain.
10. At what CD4 count should MAC (Mycobacterium avium complex) prophylaxis with azithromycin be initiated?
A CD4 <200 cells/mm³
B CD4 <100 cells/mm³
C CD4 <50 cells/mm³
D CD4 <350 cells/mm³
MAC prophylaxis with azithromycin 1200mg weekly is indicated when CD4 falls below 50 cells/mm³. This is the most profound level of immunosuppression. At this CD4 level, CMV retinitis surveillance (ophthalmology) is also essential. PCP prophylaxis begins at CD4 <200, and Toxoplasma at CD4 <100 in seropositive patients.